Roth Capital started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note released on Wednesday morning. The brokerage issued a buy rating and a $12.00 price objective on the biotechnology company’s stock.
Shares of Aptevo Therapeutics stock opened at $3.78 on Wednesday. The firm has a market capitalization of $86.56, a price-to-earnings ratio of -2.47 and a beta of 0.68. Aptevo Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.08 and a current ratio of 5.14.
In other Aptevo Therapeutics news, insider Marvin L. White sold 100,000 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $2.93, for a total value of $293,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 15.60% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Aptevo Therapeutics (APVO) Now Covered by Analysts at Roth Capital” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/14/aptevo-therapeutics-apvo-now-covered-by-analysts-at-roth-capital.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.